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A doxorubicin (Dox) and curcumin (Cur) combination treatment regimen has 
been widely studied in pre-clinical research. However, the nanoparticles 
developed for this combination therapy require a consecutive drug loading 
process because of the different water-solubility of these drugs. The present study 
provides a strategy for the ‘one-step’ formation of nanoparticles encapsulating 
both Dox and Cur. We took advantage of polyacrylic acid (PAA) and calcium 
carbonate (CaCO3) to realise a high drug entrapment efficiency and pH-sensitive 
drug release using a simplified preparation method. Optimisation of lipid ratios 
and concentrations of CaCO3 was conducted. Under optimal conditions, the mean 
diameter of PEGylated lipid/PAA/CaCO3 nanoparticles with encapsulated Cur 
and Dox (LPCCD) was less than 100 nm. An obvious pH-sensitive release of 
both drugs was observed, with different Dox and Cur release rates. Successful co-
delivery of Cur and Dox was achieved via LPCCD on HepG2 cells. LPCCD 
altered the bio-distribution of Dox and Cur in vivo and decreased Dox-induced 
cardiotoxicity. The current investigation has developed an efficient ternary 
system for co-delivery of Dox and Cur to tumours, using a ‘one-step’ formation 
resulting in nanoparticles possessing remarkable pH-sensitive drug release 
behaviour, which may be valuable for further clinical studies and eventual 
clinical application. 





In cancer treatment, combination therapy is widely applied in patients to achieve 
enhanced therapeutic efficacy and a reduction in side-effects. As a superior strategy to 
circumvent multi-drug resistant (MDR) effects, combination therapy is generally 
applied for advanced tumours (Misra and Sahoo, 2011, Huang et al., 2015) and in 
terminal cancer patients (Jiang et al., 2014). A large number of drug delivery systems 
(DDSs) have been developed, with the aim of achieving targeted drug delivery to 
tumour tissues and cells. However, conventional single drug DDSs cannot be used for 
combination therapy, especially for drug combinations including both lipophilic and 
hydrophilic drugs. 
Previous studies have indicated that the combination of doxorubicin (Dox) and 
curcumin (Cur) is a promising combination therapy for cancer treatment (Misra and 
Sahoo, 2011, Duan et al., 2012). Since the application of Dox is limited by 
cardiotoxicity and the emergence of the MDR effect. Cur, with a wide range of 
pharmacological effects, has been applied to overcome the MDR problem and 
ameliorate the side-effects (Duan et al., 2012, Pramanik et al., 2012). A variety of nano-
carriers has been developed in expectation of improving the solubility of Cur and 
realising co-delivery of both Dox and Cur. Wang et al. developed Cur-Dox/MPEG-PCL 
micelles (Wang et al., 2013). During their preparation, Cur and MPEG-PCL were first 
self-assembled into a core-shell structured Cur/MPEG-PCL micelle, and then Dox was 
encapsulated in a buffer (pH 7.4). Barui et al. encapsulated both Cur and Dox into a 
ligand-modified liposome using a film dispersion method and a pH gradient method, 
separately (Barui et al., 2014). In such a DDS, a separated encapsulation procedure is 
inevitable because of the different levels of water solubility of the drugs. This 
complexity in preparation restricts the potential application of such a DDS. To this end, 
a nanoplatform exploiting a ‘one-step’ formation method for combination therapies is in 
need. 
Calcium carbonate (CaCO3) has been widely studied as a carrier or component of 
nanoparticles in order to facilitate the delivery of drugs and genes (Ueno et al., 2005, 
Sharma et al., 2015). In the presence of polyanion-DNA, CaCO3 nanoparticles can be 
formed. The presence of CaCO3 precipitation might control the size of DNA/CaCO3 co-
precipitation and enhance gene delivery (Zhao et al., 2014). Moreover, the inherent pH-
sensitivity of CaCO3 might be useful to promote the dissociation of nanoparticles and 
endosome/lysosome escape under low pH conditions (Gong et al., 2015, Min et al., 
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2015). Considering the feasibility of CaCO3 formation in the presence of Ca2+ and 
CO32- ions, a promising strategy involves including CaCO3 in a DDS as an inducer of 
drug release.  
To increase the encapsulation of water soluble drug, Dox, a polyanion polyacrylic acid 
(PAA) was employed in this system. Previous studies have shown that PAA and Dox 
can form complexes with a pH-dependent interaction (Kitaeva et al., 2004). Based on 
the results of a previous study, we chose a higher molecular weight PAA to achieve a 
high Dox encapsulation and a condensed structure for the PAA/Dox complexes. 
In the current study, we designed a one-step formation method for a novel PEGylated 
lipid/PAA/CaCO3 ternary system encapsulating Cur and Dox (LPCCD) aimed at 
increased tumour inhibitory effects and decreased cardiotoxicity. After formulation 
optimisation, the pH-sensitivity, cellular uptake, in vitro tumour suppression, in vivo 
bio-distribution and safety of the LPCCD nanoparticles were studied. 
 
2. Materials and methods 
2.1 Materials and reagents 
Egg lecithin (EPC), Cur and PAA (Mw: 25 kDa) were purchased from Wako Pure 
Chemical Industries (Osaka, Japan). DSPE-020CN (N-(Carbonyl-
methoxypolyethyleneglycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 
DSPE-PEG2000) was obtained from NOF corporation (Tokyo, Japan) and 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP) was obtained from Avanti Polar Lipids 
(Alabaster, AL, USA). Doxorubicin hydrochloride (Dox) was provided by Tokyo 
Chemical Industry Co., Ltd. (Tokyo, Japan). The other inorganic chemicals were 
obtained from Nacalai Tesque (Kyoto, Japan). All organic solvents of analytical grade 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Water used in all 
experiments was prepared through Direct-Q UV (Merck Millipore, Merck KGaA, 
Darmstadt, Germany.). 
 
2.2 Cells and animals 
HepG2 liver tumour cells were obtained from RIKEN (Tokyo, Japan). All cell culture 
media were purchased from Thermo Fisher Scientific (Waltham, MA USA).  
Male ddY mice (25–27 g) and Wistar rats (230–280 g) supplied by Kyudo Co., Ltd. 
(Kumamoto, Japan) were fed a standard laboratory diet and were housed at an ambient 
temperature and humidity in air-conditioned chambers before the experiments. All 
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animal experiments were conducted in full compliance with the Guideline for Animal 
Experimentation at Nagasaki University. 
 
2.3 Preparation and optimisation of nanoparticles 
The ethanol injection method was used in the preparation of this ternary system. A 1 M 
CaCl2 ethanol solution, a 3 mg/mL Cur ethanol solution and a 10 mg/mL Dox water 
solution were prepared as stock solutions. A certain amount of EPC, DOTAP and 
DSPE-PEG was dissolved in 8 mL of ethanol. Under stirring, a CaCl2 solution, 1 mL of 
Cur solution and 0.5 mL of Dox solution were added dropwise to the lipid mixture 
solution in sequence and stirred for another 1 h at room temperature (ethanol phase). 
Meanwhile, a 5 mM Na2CO3 water solution including 1.25% glucose was prepared. 
After a certain amount of PAA was solubilised in 40 mL of the Na2CO3/glucose 
solution and stirred for another 1 h (water phase), the ethanol phase was added dropwise 
to the water phase with stirring for 2 h at room temperature. Then, the obtained mixture 
was maintained in a rotary evaporator (EYELA, Tokyo, Japan) under vacuum for 30 
min at 40°C to evaporate the ethanol and concentrate the mixture to 10 mL. The 
obtained suspension was vortexed for 3 min and passed through a 0.8 μm filter to 
produce the LPCCD nanoparticles. In the preparation of a LPC blank carrier, the Cur 
and Dox solutions were not added, and the procedure was identical in all other respects. 
In the optimisation of the formulation, the CaCO3 concentration was varied and the ratio 
of PAA/DOTAP and DOTAP/EPC were studied. The diameter, polydispersity index 
(PDI), zeta potential and drug content of the nanoparticles were taken into consideration 
for the evaluation and confirmation of the optimised formulation. 
 
2.4 Characterisation of LPC and LPCCD  
The particle size, PDI and zeta potential of the LPC and LPCCD were assessed using a 
Zetasizer Nano ZS (Malvern, UK). To investigate the size variation of the lipid 
nanoparticles under different pH conditions, 0.01 M pH 7.4 Hepes buffer and 0.01 M 
pH 5.5 Mes buffer were used for the dilution of the nanoparticles at a ratio of 3:1 (v/v). 
Changes in the size distribution of the LPC and LPCCD were recorded after a 2 h 
incubation.  
The drug content, drug loading capacity (DL) and entrapment efficiency (EE) of Dox 
and Cur were determined using high performance liquid chromatography (HPLC) with 
a UV detector (SPD-10A, Shimadzu, Kyoto, Japan). Briefly, 50 μL of the LPCCD 
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solution was added to 5 mL of a 1% Triton X-100 solution. The solution was sonicated 
for 1 min and centrifuged at 12,000 × g for 10 min (KUBOTA, Tokyo, Japan). The 
supernatant was analysed using a mobile phase of 5% acetic acid:acetonitrile = 60:40 
(v/v) at λ = 420 nm to determine the Cur concentration in the LPCCD. For the 
measurement of Dox concentration, a mobile phase of 0.3% sodium dodecyl sulphate 
(adjusting pH to 2.7 using phosphoric acid):acetonitrile:methanol = 60:40:1 (v/v) at λ = 
484 nm was used. The mobile phase was delivered at 1 mL/min through a C18 column 
(Cosmosil-Pak, 4.6 × 150 mm, internal diameter 5 μm). DL and EE were calculated in 
accordance with the following equations: 
100
lesnanopartic of weight  totalltheoretica
drug loaded ofweight %) (wt. DL                 (1) 
100
drug feeding ofweight 
drug loaded ofweight %) (wt. EE                  (2) 
 
2.5 pH-sensitive drug release  
Drug release behaviour was monitored using a membrane dialysis technique. 0.01 M pH 
7.4 Hepes buffer (including 0.1% Tween 80) and 0.01M pH 5.5 Mes buffer (including 
0.1% Tween 80) were prepared to simulate the physiological environment and 
lysosome/endosome microenvironment, respectively. A LPCCD solution (0.2 mL) was 
placed into a dialysis bag (molecular weight cutoff, 12 kDa) and exposed to 20 mL of 
pH 7.4 and pH 5.5 buffer. In addition, 0.2 mL of LPCCD solution with 10% foetal 
bovine serum (FBS; v/v) was also exposed to 20 mL of pH 7.4 buffer to determine the 
effect of FBS on the stability of LPCCD. In a shaking water bath, the drug release was 
determined for 30 h at 37°C. At certain intervals, 0.1 mL of medium was withdrawn and 
the same amount of fresh medium was replenished. The concentration of Dox and Cur 
was determined using HPLC. 
 
2.6 Haemolysis activity  
Fresh rat arterial blood was centrifuged at 1630 × g for 10 min in pH 7.4 phosphate- 
buffered saline (PBS) to collect the red blood cells (RBCs). This step was repeated three 
times and the RBCs were resuspended in PBS. LPC and the liposome (prepared using 
the same amount of EPC, DOTAP and DSPE-PEG with the ethanol injection method) at 
various concentrations of lipids were incubated with a 10 % (v/v) RBC suspension at a 
ratio of 1:4 (v/v) and shaken in a water bath at 37°C for 1 h. Milli-Q water and PBS 
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were incubated with the RBC suspension using the same procedure, as a positive and 
negative control, respectively. After a 1 h incubation, the mixture was centrifuged at 
1,630 × g for 10 min and the supernatant was analysed using a spectrophotometer (UV-
1600, Shimadzu, Kyoto, Japan) at λ = 550 nm. The haemolysis percentage was 
calculated using the following equation:  
100
controlnegativeofabsorbance－controlpositiveofabsorbance
controlnegativeofabsorbance－sampleofabsorbance(%)Haemolysis  (3) 
 
2.7 In vitro cellular uptake  
HepG2 cells were cultured in Dulbecco’s modified Eagle medium (DMEM) including 
10% FBS and 10,000 U/mL of penicillin/streptomycin at 37°C, 5% CO2 and 90% 
relative humidity. For the cellular uptake evaluation, the cells were seeded at a density 
of 1×105 cells/well in six-well plates. After a 12 h incubation, the cells were incubated 
with free Dox, Dox + Cur (1:1, mol/mol) and LPCCD (final concentration of 5 μM of 
Dox) in FBS-free medium for a certain period of time at 37°C. Then, the supernatant 
was removed and the cells were washed using PBS (pH 7.4) three times. The cells were 
fixed in 4% paraformaldehyde for 15 min and washed using PBS again. After two drops 
of Slow Fade Diamond® (Thermo Fisher Scientific) were added, the samples were 
observed using confocal microscopy (Carl Zeiss Microimaging GmbH, Jena, Germany). 
To quantify the DOX cellular uptake, a fluorescence-activated cell-sorting flow 
cytometer (Beckman Coulter, Brea, CA, USA) was employed. After incubation with the 
samples for 4 h, the supernatant was removed. The cells were washed with PBS and 
trypsinised, in accordance with a standard protocol. After resuspension of the cells in 
0.5 mL of PBS, the mean fluorescence intensity of the Dox was detected.  
 
2.8 In vitro cytotoxicity 
For an evaluation of cytotoxicity, the cells were seeded in 96-well plates at a density of 
1 × 104 cells/well. Dox, Dox + Cur (1:1, mol/mol), LPC and LPCCD at various 
concentrations were added to the wells after a 12 h incubation. The cells were further 
incubated for 48 h, the medium was removed and the cells were washed with PBS. 
DMEM (100 µL) including 10 µL of cell counting kit-8 (Dojindo, Kumamoto, Japan) 
was added to each well and incubated for 1 h. The absorbance was measured at 450 nm 
using a microplate photometer (Multiskan™ FC, Thermo Fisher Scientific). Blank wells 
and untreated cells served as a negative control and positive control, respectively. 
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2.9 Bio-distribution of the nanoparticles 
A free Dox + Cur solution and LPCCD (at an equivalent Dox concentration of 0.4 
mg/mL and Cur at 0.24 mg/mL) were intravenously injected in ddY mice at a Dox dose 
of 3 mg/kg. Mice were anesthetised using a drug mix (butorphanol, medetomidine and 
midazolam) 3 h after the treatment injection. Blood was taken from the inferior vena 
cava, and the heart, liver, spleen, lung and kidney were harvested and weighed. Dox and 
Cur were extracted as reported in a previous study (Abdalkader et al., 2015). Briefly, 
organs were homogenised using a mixed solution of isopropanol and 1 M HCl (1:1, v/v) 
and incubated at 4°C for 1 h. The solutions were centrifuged at 1,630 × g for 15 min, 
and the supernatants were centrifuged again at 15,000 × g for 15 min. In the case of 
determining the drug concentration in plasma, the blood was centrifuged at 1,500 × g 
for 10 min. The plasma supernatant was mixed with an isopropanol:1 M HCl = 1:1 (v/v) 
mixture and acetonitrile for the detection of Dox and Cur. The supernatants were 
analysed using a fluorescence spectrometer (RF-5300PC, Shimadzu, Kyoto, Japan). For 
the detection of Dox, the excitation (Ex) and emission (Em) wavelength was 500 and 
590 nm, respectively. An Ex/Em of 440/500 nm was used in the detection of Cur. 
Standard curves of Dox and Cur were prepared using blank organ extracts. 
 
2.10 Histopathological analysis of cardiotoxicity 
Free Dox and LPCCD were injected intravenously in ddY mice at a 5 mg/kg Dox 
equivalent once daily for 3 days. Six hours following the last injection, a 
histopathological analysis was performed on the heart. Briefly, after tissue perfusion, 
the heart was harvested and fixed using 4% paraformaldehyde, immersed in sucrose 
solution and embedded in O.C.T compound. The frozen tissues were sliced at a 5 μm 
thickness and stained using haematoxylin and eosin (H&E). A morphological evaluation 
was performed using a microscope (Carl Zeiss, Jena, Germany).  
 
2.11 Statistical analysis 
The data are presented as mean ± standard deviations (SD) of at least three independent 
experiments. Significant differences were identified using Student’s t-test and one-way 
ANOVA analysis followed by Bonferroni’s post hoc test. A P-value of less than 0.05 




3.1 Optimisation of the LPCCD  
‘One-step’ formation of nanoparticles with encapsulated Dox and Cur was achieved 
using the ethanol injection method. The concentration of CaCO3, and the PAA/DOTAP 
and EPC/DOTAP weight ratios were optimised based on the characteristics of the 
nanoparticles and the loaded drug content.  
The diameter of the nanoparticles prepared using various concentrations of CaCO3 was 
approximately 100 nm (Fig. 1). As the concentration of CaCO3 increased, a charge 
reversal was observed in the zeta potential. At 20 mM of CaCO3, both Cur and Dox 
exhibited the highest level of encapsulation. Given that the smallest diameter and PDI 
were detected at 20 mM of CaCO3, this concentration of CaCO3 was used in the 
following experiments. 
In terms of the PAA/DOTAP weight ratio (Fig. 2), the diameter of both the LPC and the 
LPCCD was less than 100 nm, except for the LPCCD prepared at 16:5, while poor 
mono-dispersity was shown at a low weight ratio (4:5). Charge reversal was observed 
on the addition of PAA. The charge potential of the nanoparticles decreased after Dox 
encapsulation. The highest dox encapsulation was achieved at a PAA/DOTAP weight 
ratio of 8:5. Moreover, increased PAA restricted the encapsulation of Cur. Therefore, at 
a PAA/DOTAP weight ratio of 8:5, the balance in nanoparticle size, PDI and drug 
content was the best. 
Next, we optimised the EPC/DOTAP weight ratio (Fig. 3). Nanoparticles less than 100 
nm in diameter were achieved at an EPC/DOTAP weight ratio of 4:1. The PDI had a 
tendency to increase at higher ratios of EPC/DOTAP. Cur encapsulation was the best at 
an EPC/DOTAP weight ratio of 4:1. As the EPC/DOTAP weight ratio increased to 6:1, 
Dox encapsulation was greatly decreased. Therefore, taking the characteristics of the 
nanoparticles and the drug loading data into consideration, the LPCCD prepared at an 
EPC/DOTAP weight ratio of 4:1 were optimal. 
 
3.2 Characterisation of the LPC and LPCCD 
Under the optimised conditions, the diameters of both LPC and LPCCD were less than 
100 nm with a reasonable mono-dispersity (Table. 1). The entrapment efficiency of 
both Dox and Cur was higher than 80% showing a molar ratio of Dox/Cur of 
approximately 1:1 (Table. 2). Next, we measured the UV spectrum of Dox and Cur in 
the LPCCD (Fig. 4). It was clear that the characteristic peak of Cur around 430 nm 
overlapped with that of the LPCCD. However, one of the Dox characteristic peaks 
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around 250 nm shifted to the left side of the curve of the LPCCD and the other Dox 
peaks around 500 nm decreased.  
 
3.3 pH-sensitivity and stability of the nanoparticles 
DDSs with pH-sensitivity are promising for efficient intracellular drug release. The 
variation of the particle size distributions of both LPC and LPCCD when mixed with 
buffer solutions at different pH values might indicate a morphological change in the 
nanoparticles (Supplementary Fig. 1). In particular, in the LPCCD sample, the curve at 
pH 5.5 shifted slightly to the right and the intensity decreased.  
The drug release behaviour at different pH values was also studied. Both Dox and Cur 
release exhibited a noticeable sensitivity to pH, which was particularly pronounced for 
Dox release (Fig. 5A). As the pH decreased from 7.4 (physiological conditions) to 5.5 
(lysosome/endosome environment), a sharply increased release of Dox was observed. 
However, Cur showed a delayed release at pH 5.5 compared with Dox. In addition, the 
release behaviour of both Dox and Cur in the presence of 10% FBS was 
indistinguishable from that in the samples without FBS (Fig. 5B).  
 
3.4 Evaluation of the cellular uptake of the LPCCD 
Both Dox and Cur possess fluorescence that that can be used to indicate their 
intracellular distribution. Using microscopy, Dox was clearly observed to enter the 
nucleus in the free drug groups, while the fluorescence of Cur was undetectable (Fig. 6). 
In the case of the LPCCD groups, the cellular uptake of both of Dox and Cur increased 
along with time until 8 h, at which apoptosis may have occurred as indicated by nuclear 
perforations. The released Dox overlapped with Cur, which is indicated by a yellow 
colour. It was clear that LPCCD enhanced the cellular uptake of Cur into the cytoplasm 
and the increased accumulation of Dox in the nucleus might have resulted from pH-
sensitive drug release. However, the cellular uptake and nuclear penetration of Dox in 
the LPCCD groups was not as good as in the free drug groups. The quantitation of 
cellular uptake was conducted using a flow cytometer, and it was demonstrated that the 
mean fluorescence intensity of cells treated using LPCCD was approximately half that 
of the free drug groups (Fig. 7). 
 
3.5 Cytotoxicity and safety of the nanoparticles 
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An in vitro cell-growth inhibition study was performed using HepG2 cells (Fig. 8). At a 
low concentration of Dox, the inhibitory effect of the free Dox and LPCCD on cell 
growth was slightly inferior to that of the free drug combination. As the drug 
concentration increased, LPCCD exhibited higher cytotoxicity compared with Dox and 
Dox + Cur groups (Fig. 8A). The IC50 of Dox, Dox + Cur and the LPCCD was 0.1645, 
0.0491 and 0.1256 µM, respectively. The LPC blank carrier produced no inhibitory 
effects on the growth of tumour cells at corresponding concentrations of EPC (Fig. 8B). 
Meanwhile, significant levels of haemolysis were not produced by either the LPC or 
liposomes prepared without PAA and CaCO3 (Supplementary Fig. 2). Even at the 
highest concentration of total lipid, the haemolysis was below 5% and the nanoparticles 
were deemed to possess no haemolytic activity in vitro. Importantly, the CaCO3 was 
verified to not produce a burst release of Ca2+ ions under physiological conditions, 
which might affect the stability of erythrocytes. Therefore, the nanoparticles were 
suitable for an in vivo study. 
 
3.6 Bio-distribution of Dox in mice 
We checked the prolonged blood circulation of LPCCD in ddY mice (Fig. 9). LPCCD 
significantly increased the blood concentration of Dox and Cur at 3 h as compared with 
the free drugs groups (Fig. 9A and D). The accumulation of Dox and Cur in the spleen 
from delivered LPCCD was significantly increased compared with the free drugs groups 
(Fig. 9B and E). In the liver, lung and kidney, both Dox and Cur showed decreased 
distribution. Meanwhile, an obviously reduced distribution of Dox to the heart from the 
delivered LPCCD was observed related to the free Dox group. Distribution patterns of 
Dox and Cur in LPCCD group indicated apparently different accumulations between 
Dox and Cur, especially in the spleen and lung. This implied that a part of LPCCD were 
broken during blood circulation and subsequently released Dox and Cur partitioned 
from blood to tissues. As clearly shown from the obtained tissue/plasma ratios, 
nanoparticle formulation greatly decreased the partition of Dox and Cur from plasma to 
tissue (Fig. 9C and F). It is reasonable to conclude that the LPCCD avoid the fast 
clearance of drugs in circulation and alter the bio-distribution of Dox and Cur in vivo. 
 
3.7 Evaluation of the cardiotoxicity induced by Dox 
A histological assay was performed on heart cryosections to evaluate Dox-induced 
cardiotoxicity. The morphology of the tissue was observed using light microscopy after 
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a H&E stain on cross-sections of the cardiac tissue (Fig. 10). Normal tissue morphology 
was observed in the saline group. A number of cells with significant oedema are 
indicated using black arrows in the free Dox-treated group, indicating inflammation 
after continuous doses. In addition, hypertrophic cardiac cells, identified from their 
elongated nuclei, were revealed in the free Dox-treated group (white arrows). In 
contrast, no inflammatory cells or hypertrophic cardiac cells were observed in the 
LPCCD group at an equivalent dose of Dox.  
 
4. Discussion 
Combination therapy, with its obvious advantages, has been generally employed as a 
therapeutic regimen for cancer treatments. The sole use of Dox, a widely used 
chemotherapeutic drug in clinical treatment, is associated with the development of 
MDR and cardiotoxicity problems. Preclinical research has shown that combining Dox 
with Cur, which possesses promising pharmacological effects, can overcome the 
setbacks of using Dox alone (Sadzuka et al., 2012). A significant amount of research 
has been dedicated to harnessing the synergistic effects of this combination therapy in 
tumour inhibition. Micelles, nanocapsules and liposomes with functional components 
have been developed to achieve efficient co-delivery of Dox and Cur (Barui et al., 2014, 
Fang et al., 2014, Li et al., 2015). However, multi-step methods for nanoparticle 
preparation and drug encapsulation were involved. Therefore, we have developed a 
simplified method for the simultaneous encapsulation of Dox and Cur within ‘one step’, 
resulting in the LPCCD nanoparticles. The key point for the ‘one-step’ formation of the 
LPCCD was utilisation of the phenomenon that CaCl2 is soluble in ethanol. Addition of 
CaCl2 into the ethanol phase with other components including lipids, Dox, and Cur 
enabled us to form lipid/polyanion/CaCO3 ternary nanoparticles containing drugs using 
an ethanol injection method. Therefore, the formation of highly organised LPCCD was 
successfully achieved within ‘one step’. 
It has been previously reported that the complexation of PAA/Dox resulted in 
nanoparticles with a diameter ranging from 600 to 900 nm that possessed a pH 
dependent interaction, and smaller nanoparticles of approximately 200 nm were 
obtained after mixing them with liposomes (Kitaeva et al., 2004). Enlightened by this 
study, we involved the PAA/Dox unit in the LPCCD system. In terms of Cur 
encapsulation, liposomes are a good choice. Therefore, the LPCCD co-delivery system 
was developed based on the triple complexation of lipid/Cur, PAA/Dox and CaCO3. To 
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decrease the particle size of the nanoparticles and improve the Dox loading, a high 
molecular weight PAA (25 kDa) was utilised. Given that interaction between PAA/Dox 
complexes and lipids would affect the stability of the lipid bilayer and mono-dispersity 
of the final ternary system, a ‘one-step’ formation method with both encapsulated Dox 
and Cur was developed and optimised. Importantly, the use of a certain amount of the 
DOTAP positive lipid instead of the EPC neutral lipid was the key factor in achieving a 
successful ‘one-step’ formation. 
During the optimisation of the formation conditions of the LPCCD, the concentration of 
CaCO3, and the PAA/DOTAP and EPC/DOTAP weight ratios were important factors in 
determining the particle size, PDI, and drug content (Figs. 1-3). Increasing the 
concentration of CaCO3 during the formation of the LPCCD caused the surface charge 
to change from negative to positive (Fig. 1C). This might be caused by the charge 
neutralisation of PAA by the Ca2+ ion. The Cur content decreased at 10 mM CaCO3. A 
strong electrostatic interaction between polyanion PAA and the lipid bilayer containing 
the DOTAP cationic lipid might interfere with the insertion of Cur. A particular 
concentration of the Ca2+ ion was required for efficient drug loading of Cur. However, 
too high of a concentration of CaCO3 might inhibit the stable formation of the 
nanoparticles. In fact, a 30 mM CaCO3 concentration resulted in an increase in the PDI 
(Fig. 1B) and flocculation (data not shown). A reduced encapsulation of Dox in the 
LPCCD at a 30 mM CaCO3 concentration was observed, possibly because of the 
filtration through filter. The electrostatic interactions between PAA and DOTAP played 
an important role in the formation of the nanoparticles (Fig. 2). Increasing the 
PAA/DOTAP ratio decreased the zeta potential, indicating that the surface of the 
nanoparticles was covered with PAA possessing carboxyl groups. Because Dox 
incorporation into the nanoparticles unexpectedly decreased the zeta potential, despite 
the cationic charge of Dox, the interaction between PAA and Dox may have inhibited 
the penetration of the PAA/CaCO3/Dox complexes into the core of the lipid 
nanoparticles, resulting in a partial shift of PAA to the surface of the nanoparticles. 
Drug encapsulation was closely related to the PAA/DOTAP ratio. Charge balance and 
electrostatic interaction among PAA, DOTAP and Dox are important for the 
encapsulation of Dox. Increasing the PAA ratio decreased Cur encapsulation because of 
the interaction with DOTAP. There is no doubt that the lipid component proportions 
(EPC/DOTAP ratio) are closely related with the characteristics of the nanoparticles (Fig. 
3). An increased amount of total lipid and the proportion of EPC increased the difficulty 
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in the formation of the nanoparticles, especially via a ‘one-step’ formation method. The 
increased weight ratio of EPC/DOTAP gave rise to a decreased positive charge density 
of the LPC. Both sharply reduced encapsulation of Dox and the increased PDI might be 
caused by the loss of LPCCD with a large size via passing through the filter. In general, 
strong negative and positive surface charge stabilise nanoparticles. This is in consistent 
with the properties of the LPCCD, since the particle size and PDI tended to be smaller 
when the zeta potential of the nanoparticles was approximately neutral (Figs 1–3). The 
formulation of LPCCD is complicated that contains several cations and anions. As 
cations, Dox, DOTAP and Ca2+ ions would interact with anion PAA and the CO32- ion. 
If we assume that nanoparticle intermediates are present, the strong negative and 
positive charge of the intermediates undergo charge neutralisation from free cations and 
anions, respectively, and as a consequence the intermediates become large. The optimal 
concentration of CaCO3, and the optimal PAA/DOTAP and EPC/DOTAP weight ratios 
were 20 mM, 8:5, and 4:1, respectively. 
Under optimal conditions, the particle size of the nanoparticles was less than 100 nm, 
indicating their successful preparation (Table 1). The nanoparticles contained a 
sufficient amount of Dox and Cur (Table 2). The entrapment efficiencies for Dox and 
Cur were very high (Table 2). The encapsulation of Dox and Cur in the LPCCD was 
verified by recording their UV spectrum (Fig. 4). The characteristic Dox peak around 
500 nm decreased, whereas the peak around 250 nm shifted to the left. This might be 
caused by a difference in the ionisation condition of Dox through neutralisation with 
PAA and the CO32- ion. Under an acidic environment, the disruption of CaCO3 and the 
dissociation of the Dox/PAA/CaCO3 complexes would occur. Therefore, a change in pH 
might influence the stability of the LPCCD (Supplementary Fig. 1). Consistent with 
the size variation, both dissociation of the PAA/Dox complexes and the destruction of 
the CaCO3 enhanced the drug release (Fig. 5A). In addition, the increased free Ca2+ ions 
might contribute to the enhanced Dox release by competitively inhibiting interaction 
with PAA. In the case of Cur, the dissociated PAA might combine with DOTAP to 
affect the stability of the lipid bilayer leading to a retarded release of Cur. Since the 
drug release was similar in 10% FBS (Fig. 5B), it is rational to suppose that the LPCCD 
can remain stable in in vivo circulation.  
In the development of liposomes, pH-sensitive drug release has been pursued because of 
the stability of liposomes leading to a slow and incomplete drug release. Encapsulation 
of calcium phosphate and calcium carbonate during the formation of liposomes and 
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nanoparticles has resulted in an impressive pH-sensitivity and enhanced drug delivery 
(Li et al., 2010, Li et al., 2012). In the lysosome/endosome, low pH promotes an 
increase of calcium and bicarbonate/carbonate ions, the resulted osmotic swelling 
leading to a fast release of drugs into the cytoplasm (Kim et al., 2013). To date, the 
delivery of DNA via liposomes in the presence of calcium phosphate and calcium 
carbonate was particularly intriguing in view of enhancing transfection efficiency (Hu et 
al., 2013, Zhao et al., 2014). The structural similarity between PAA and DNA in terms 
of the presence of large amounts of anion groups means that the co-precipitation of Ca2+, 
Dox and PAA with CO32- in the presence of the phospholipid might result in pH-
sensitive in drug release. In the current study, the optimisation of the formulation clearly 
showed that the ratio between PAA, lipid and CaCO3 was closely related with the 
characteristics of the formed nanoparticles and the drug loading efficiency (Figs. 1–3). 
An obvious pH-sensitive drug release was observed for both Dox and Cur (Fig. 5A). 
Not only the pH sensitivity of the combination between PAA and Dox, but also the 
destruction of CaCO3 under an acidic environment might promote the burst release of 
Dox. Simultaneously, because of the existence of an electrostatic interaction between 
PAA and DOTAP, disruption of the PAA/Dox/CaCO3 complexes at pH 5.5 resulted in 
instability in the lipid bilayer promoting a delayed release of Cur.  
To guarantee the stability and mono-dispersity of the LPCCD nanoparticles, a certain 
amount of DSPE-PEG was necessary to prevent aggregation during the ‘one-step’ 
formation that involved complex electrostatic interactions between multiple components. 
The peripheral PEG moieties imparted stability to the LPCCD in the presence of FBS 
(Fig. 5B) and safety in terms of haemolysis (Supplementary Fig. 2). In addition, the 
blood circulation of the LPCCD was also greatly prolonged by the PEG coating by 
preventing phagocytosis by the immune cells of the reticuloendothelial system (Fig. 9). 
However, DSPE-PEG is a double-edged sword. A high ratio of DSPE-PEG in a lipid 
bilayer might suppress the cellular uptake of LPCCD, as potentially indicated by the 
reduced nuclear penetration of Dox (Figs. 6–7). The cytotoxicity of LPCCD on tumour 
cells was slightly inferior to the free drug combination group, despite a significantly 
reduced cellular uptake of Dox. However, taking the increased cellular uptake of Cur 
from the LPCCD into consideration, it is reasonable to conclude that the LPCCD 
promoted the antitumor effects of Dox and Cur via efficient co-delivery. For future 
tumour-selective delivery of LPCCD, the incorporation of tumour-specific ligands 
would be required. 
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The realisation of the synergistic effects of combination therapies relies on the efficient 
co-delivery of drugs to targeted organs. Generally, the in vivo bio-distribution behaviour 
of drugs is diverse because of the different metabolic pathways involved. With the 
employment of nanoparticles, the component drugs are capable to achieve desired 
spatiotemporal distribution in vivo. As shown in Fig. 9, the altered accumulation of both 
Dox and Cur in organs from the LPCCD compared with the free drugs group was 
observed in the in vivo distribution study. The increased plasma concentration and 
similar bio-distribution of the Dox and Cur in vivo from the LPCCD nanoparticles 
compared with the free drugs group provide a foundation for the realisation of enhanced 
synergistic effect of the combination therapy. In addition, the decreased distribution of 
Dox to the heart in the LPCCD group was consistent with the results from the 
histological assay of ameliorated cardiotoxicity (Fig. 10). Therefore, it is reasonable to 
hypothesise that co-delivery of Dox and Cur using LPCCD would be an effective 
delivery system with high safety. 
 
5. Conclusions 
We have successfully developed a CaCO3-encapsulated PAA-stabilised lipid ternary 
system for Dox and Cur combination therapy. With the use of polyanion-PAA and 
CaCO3, the LPCCD co-delivery system was achieved using a ‘one-step’ formation 
method and it possesses a robust pH-sensitive drug release. A narrow size distribution 
of nanoparticles of approximately 100 nm in diameter was achieved. The entrapment 
efficiencies of Dox and Cur in the LPCCD were high. Moreover, the LPCCD produced 
significant cytotoxicity in tumour cells and decreased cardiotoxicity compared with free 
Dox. In summary, the LPCCD nanoparticles have potential in cancer therapy and this 
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Table 1. Diameter, PDI and zeta potential of LPCs and LPCCDs 
Group Diameter (nm) PDI Zeta potential (mV) 
LPC 91.73 ± 1.15 0.140 ± 0.005 -2.07 ± 0.46 
LPCCD 99.17 ± 0.31 0.189 ± 0.003 -2.82 ± 0.28 
 
 
Table 2. Drug content, drug loading (DL) and entrapment efficiency (EE) of LPCCDs 
Drug Content (mg/mL) DL(%) EE(%) 
Dox 0.405 ± 0.022 2.59 ± 0.14 80.95 ± 4.33 









Fig. 1 The (A) diameter, (B) polydispersity index and (C) zeta potential of LPCCD and 
LPC and (D) Cur and Dox drug content in LPCCD with variation of the 





Fig. 2 The (A) diameter, (B) polydispersity index and (C) zeta potential of LPCCD and 
LPC and (D) Cur and Dox drug content in LPCCD with varied PAA/DOTAP 




Fig. 3 The (A) diameter, (B) polydispersity index and (C) zeta potential of LPCCD and 
LPC and (D) Cur and Dox drug content in LPCCD with varied EPC/DOTAP 










Fig. 5 Drug release behaviour of LPCCD. (A) pH-sensitive drug release of LPCCD in 
0.01 M pH 7.4 Hepes buffer (including 0.1% Tween 80) and 0.01 M pH 5.5 Mes 
buffer (including 0.1% Tween 80). (B) LPCCD alone or mixed with 10% FBS in 
0.01 M pH 7.4 Hepes buffer (including 0.1% Tween 80). Each point represents 






Fig. 6 Cellular uptake of free Cur, free Dox and free Dox + Cur at 2 h, and LPCCD at 
2, 4 and 8 h, observed using confocal microscopy (at an equivalent 







Fig. 7 Cellular uptake of free Dox, free Dox + Cur and LPCCD at 4 h, as detected 





Fig. 8 Cytotoxicity of (A) free Dox, free Dox + Cur, LPCCD and (B) LPC, as detected 
using Cell counting kit-8. Each point represents the mean ± SD of three 
experiments. Significant differences from LPCCD and free Dox group are 






Fig. 9 Bio-distribution of doxorubicin (Dox) and curcumin (Cur) after intravenous 
administration of free Dox + Cur and LPCCD in mice. (A, D) Plasma 
concentration. (B, E) Accumulation in tissues. (C, F) Tissue/plasma ratio. Each 
bar represents the mean ± SD of three experiments. Significant differences from 
the free Dox + Cur group are represented as *p<0.05, **p<0.01, ***p<0.001 for 





Fig. 10 Histopathological study of cardiotoxicity in mice treated with saline, free Dox 
and LPCCD. The presence of hypertrophic cardiac cells is indicated by white 
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Supplementary Fig. 1 Particle size distributions of LPC and LPCCD in 0.01 M pH 7.4 





Supplementary Fig. 2 Haemolysis activity of liposomes (prepared without drugs, PAA 
and CaCO3) and LPC at different total lipid concentrations.  
 
